ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury
Temporary Authorization for Named Use (ATUn) showed promising efficacy in renal diseases
Evaluation of the clinical activity by dosage level of CER-001 in the prevention of Acute Kidney Injury in ICU patients with septicemia
A potentially modifying effect on the progression of the inflammatory cascade in sepsis
Pending positive data, the company aims to move into Phase 2b by end of 2021
Regulatory News:
ABIONYX Pharma (
FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that it has received authorization from the Italian authorities to launch a clinical trial named